The delay in COVID-19 testing in the United States meant that for weeks doctors and public officials were flying blind about who was infected and where major outbreaks were located.
As former FDA Principal Deputy Commissioner Joshua Sharfstein told The New Yorker: "You certainly wouldn't want to say, 'Any lab can advertise a coronavirus test.'
As the crisis worsened and the testing shortage drew headlines, the FDA simplified the process.
This tragic testing delay has brought national attention to the FDA's longstanding, overly cautious approach to regulating American health care.
But the COVID-19 testing debacle underscores the limits of those reforms.